Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.
The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback